A Conduit of Mostly Non Mainstream News / Information – without Political Correctness…
The secret is out: marijuana is medicine. And not to the surprise of the pharmaceutical industry, who is slowly but surely gaining exclusive rights to the medical properties of this age-old plant.
But wait. How can a company, other than Monsanto, patent a plant? That’s not a serious question, but it brings up a serious point. Patents on marijuana have yet to cover genetic modifications of the plant itself, but rather involve the cannabinoids found in marijuana that are responsible for its medical effects.
Phytocannabinoids in the treatment of cancer (Patent No. US20130059018)
The most recent patent filing on cannabinoids comes from none other than GW Pharmaceuticals – the UK-based company that manufactures Sativex (1). Sativex is an oral spray that contains cannabinoids derived from the cannabis plant itself, specifically THC and CBD. Although Sativex is not yet available in the U.S., it has already gained approval in Canada, the UK and eight other European countries.
GW Pharma has been quick to recognize the market potential of cannabis and their most recent patent application makes this more than clear. Just from the title of the patent, one gets a good sense of what GW Pharma has been trying to claim as their own. “Phytocannabinoids” simply means cannabinoids derived from plants, referring to the cannabis plant in this case.
Unsurprisingly, it appears as though GW Pharma encountered difficulties in trying to claim such a broad “invention”. In fact, the updated version of their patent application shows that more than half of their original patent claims were retracted, and for good reason too. Looking back in time, GW Pharma made claims to just the use of isolated cannabinoids in the treatment of cancer, which is no more of an invention than it is a theft from individuals who first proclaimed marijuana’s cancer-fighting abilities decades ago.
On the other hand, GW Pharma’s remaining claims might just pass through the Patent Office without further questioning. GW Pharma seems to be familiar with the pharmaceutical industry’s shrewd patent strategies, which involves modifying pre-existing compounds that have already been proven to work.
In this case, all GW Pharma had to do was claim that they invented a cannabis-based botanical drug substance for treating cancer – botanical drug substance meaning any form of marijuana prepared by methods as simple as aqueous or ethanolic extraction. There you have it. GW Pharma invented neither cannabis nor a method of extraction, but still consider themselves to be inventors of “phytocannabinoids in the treatment of cancer”.
Cannabinoids as antioxidants and neuroprotectants (Patent No. US6630507)
Perhaps the most infamous marijuana-related patent belongs to the U.S. federal government themselves. Indeed, while federal agents have been keeping busy trying to defend their stance on pot prohibition, they also made sure to file patents on the medical components of the very same Schedule I drug. The funny thing is, this particular patent dates all the way back to 1998 when Bill “didn’t inhale” Clinton was still president.
Although federal patent writers made sure to include a long list of synthetic cannabinoids within their claims, carefully tucked away is none other than cannabidiol, also known as CBD.